SATELLOS BIOSCIENCE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.43 CAD | +7.50% |
|
-4.44% | 0.00% |
| 27/03 | Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 27/03 | Satellos Bioscience Announces FY 2023 Results | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 32.97M 45.07M 2.75B |
|---|---|---|---|---|---|
| Net income 2024 * | -15M -20.5M -1.25B | Net income 2025 * | -11M -15.04M -918M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.11
x | P/E ratio 2025 * |
-2
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.55% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +7.50% | ||
| 1 week | -4.44% | ||
| Current month | -4.44% | ||
| 1 month | -14.00% | ||
| 3 months | -20.37% | ||
| 6 months | +22.86% |
1 week
0.38
0.45
1 month
0.380.54
Current year
0.380.80
1 year
0.290.80
3 years
0.221.90
5 years
0.221.90
10 years
0.221.90
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Gleeson
FOU | Founder | 68 | 01/18/01 |
Michael Rudnicki
FOU | Founder | - | 01/18/01 |
| Director of Finance/CFO | - | 01/23/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | - |
Geoff MacKay
CHM | Chairman | 57 | 01/18/01 |
William McVicar
BRD | Director/Board Member | 66 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/24/06 | 0.43 | +7.50% | 39,001 |
| 03/24/03 | 0.4 | -2.44% | 124,632 |
| 02/24/02 | 0.41 | -2.38% | 148,304 |
| 01/24/01 | 0.42 | -6.67% | 61,100 |
| 30/24/30 | 0.45 | 0.00% | 3,000 |
Delayed Quote Toronto S.E., May 07, 2024 at 01:29 am IST
More quotes
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.
Calendar
14/05/2024
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.43
CAD
Average target price
1.2
CAD
Spread / Average Target
+179.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 32.97M | |
| +9.15% | 105B | |
| -1.08% | 104B | |
| +5.79% | 22.94B | |
| -11.55% | 22.34B | |
| -7.01% | 19.25B | |
| -37.08% | 17.08B | |
| -9.91% | 16.96B | |
| +7.55% | 14.16B | |
| +40.04% | 12.63B |
- Stock Market
- Equities
- MSCL Stock